Mabwell (Shanghai) Bioscience Co., Ltd. (SHA:688062)
China · Delayed Price · Currency is CNY 24.06
-1.54 (-6.02%)
Sep 11, 2026, 3:00 PM CST
SHA:688062 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 870.17 | 658.69 | 199.62 | 127.68 | 27.6 | 15.88 |
Other Revenue | 3.82 | 3.82 | 0.16 | 0.15 | 0.13 | 0.35 |
| 873.99 | 662.52 | 199.78 | 127.84 | 27.73 | 16.23 | |
Revenue Growth | 371.36% | 231.62% | 56.28% | 361.03% | 70.88% | 206.03% |
Cost of Revenue | 130.89 | 75.73 | 34.48 | 7.3 | 2.01 | 5.22 |
Gross Profit | 743.1 | 586.79 | 165.3 | 120.53 | 25.72 | 11 |
Selling, General & Admin | 519.57 | 493.83 | 405.2 | 368.36 | 267.62 | 189.16 |
Research & Development | 1,016 | 976.96 | 782.87 | 835.78 | 758.61 | 622.51 |
Other Operating Expenses | 28.21 | 6.81 | 4.42 | 3.8 | 1.88 | 0.8 |
Operating Expenses | 1,572 | 1,479 | 1,193 | 1,208 | 1,028 | 812.44 |
Operating Income | -828.92 | -891.85 | -1,027 | -1,087 | -1,002 | -801.44 |
Interest Expense | -111.31 | -90.85 | -57.78 | -13.35 | -10.3 | -6.41 |
Interest & Investment Income | 9.68 | 7.61 | 20.92 | 46.88 | 45.75 | 7.38 |
Currency Exchange Gain (Loss) | -3.55 | -3.55 | 0.28 | -0.01 | 0.16 | -0.24 |
Other Non Operating Income (Expenses) | -18.26 | 3.29 | -6.22 | -1.74 | -1.82 | 2.63 |
EBT Excluding Unusual Items | -952.36 | -975.36 | -1,070 | -1,056 | -968.59 | -798.07 |
Gain (Loss) on Sale of Investments | -10.62 | -8.48 | -3.73 | -4.69 | 1.08 | -0.23 |
Gain (Loss) on Sale of Assets | 0.4 | 0.1 | -0.11 | -0.01 | 0.33 | 2.06 |
Asset Writedown | 7.21 | - | - | -3.56 | - | - |
Other Unusual Items | 27.34 | 27.34 | 26.38 | 8.61 | 9.06 | 23.54 |
Pretax Income | -928.03 | -956.39 | -1,047 | -1,055 | -958.13 | -772.7 |
Income Tax Expense | 16.2 | 15.86 | -0.91 | 3.52 | - | - |
Earnings From Continuing Operations | -944.23 | -972.26 | -1,047 | -1,059 | -958.13 | -772.7 |
Minority Interest in Earnings | 4.51 | 2.92 | 2.65 | 5.38 | 2.89 | 3.11 |
Net Income | -939.72 | -969.33 | -1,044 | -1,053 | -955.23 | -769.59 |
Net Income to Common | -939.72 | -969.33 | -1,044 | -1,053 | -955.23 | -769.59 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 406 | 399 | 400 | 399 | 391 | 299 |
Shares Outstanding (Diluted) | 406 | 399 | 400 | 399 | 391 | 299 |
Shares Change | 1.73% | -0.27% | 0.24% | 1.93% | 30.74% | 5.32% |
EPS (Basic) | -2.31 | -2.43 | -2.61 | -2.64 | -2.44 | -2.57 |
EPS (Diluted) | -2.31 | -2.43 | -2.61 | -2.64 | -2.44 | -2.57 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -897.32 | -447.93 | -1,287 | -1,283 | -1,264 | -639.91 |
Free Cash Flow Per Share | -2.21 | -1.12 | -3.22 | -3.21 | -3.23 | -2.14 |
Gross Margin | 85.02% | 88.57% | 82.74% | 94.29% | 92.75% | 67.81% |
Operating Margin | -94.84% | -134.62% | -514.17% | -850.65% | -3615.06% | -4939.16% |
Profit Margin | -107.52% | -146.31% | -522.53% | -824.05% | -3445.00% | -4742.85% |
Free Cash Flow Margin | -102.67% | -67.61% | -643.96% | -1003.35% | -4559.01% | -3943.69% |
EBITDA | -646.59 | -710.88 | -914.86 | -1,013 | -937.96 | -739.4 |
EBITDA Margin | -73.98% | -107.30% | - | - | - | - |
D&A For EBITDA | 182.33 | 180.97 | 112.36 | 74.43 | 64.43 | 62.04 |
EBIT | -828.92 | -891.85 | -1,027 | -1,087 | -1,002 | -801.44 |
EBIT Margin | -94.84% | -134.62% | - | - | - | - |
Revenue as Reported | 873.99 | 662.52 | 199.78 | 127.84 | 27.73 | 16.23 |